1. Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut;
2. Institute for Next Generation Healthcare, Department of Genetics and Genomic Sciences, and
3. Division of Clinical Immunology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York;
4. Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Department of Pediatrics, and Department of Immunology and Genomic Medicine, National Jewish Health, Denver, Colorado;
5. Service de Pneumologie, UNICAEN, Normandie University, Caen, France;
6. ASU-Banner Neurodegenerative Disease Research Center, Arizona State University, Tempe, Arizona;
7. Section of Pharmacology, Otto Loewi Research Center, Medical University of Graz, Graz, Austria;
8. Discovery Biology, Discovery Sciences, Research & Development, AstraZeneca, Gothenburg, Sweden;
9. BioPharmaceuticals Research & Development Cell Therapy, Research, and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), AstraZeneca, Gothenburg, Sweden;
10. Department of Medicine, Baylor College of Medicine, Houston, Texas; and
11. Emerging Innovations, Discovery Sciences, Research & Development, AstraZeneca, Boston, Massachusetts